Litchfield Hills analyst Theodore O’Neill initiated coverage of DarioHealth (DRIO) with a Buy rating and $3 price target DarioHealth is a leading digital health company revolutionizing how people with chronic conditions manage their health, the analyst tells investors in a research note. The firm says the company has a “well protected technology moat” as GLP-1s are generating a new population of members who were previously underserved.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth’s Earnings Call: Growth Amid Challenges
- DarioHealth Reports Increased Revenue Amid Rising Losses
- DarioHealth’s Hold Rating: Revenue Challenges and Future Prospects Amid Contract Renewals and Tariff Impacts
- DarioHealth price target lowered to $1.50 from $2 at Stifel
- DarioHealth reports Q1 EPS (14c), consensus (5c)